We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+18.92%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$598M
AUM Growth
+$132M
Cap. Flow
+$140M
Cap. Flow %
23.32%
Top 10 Hldgs %
44.39%
Holding
102
New
38
Increased
16
Reduced
12
Closed
21

Top Buys

Rank Stock Value
1
NICE icon
Nice
NICE
+$24.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$20.2M
3
MSFT icon
Microsoft
MSFT
+$13.9M
4
NTR icon
Nutrien
NTR
+$11.2M
5
AMZN icon
Amazon
AMZN
+$8.28M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$10.9M
2
ALBO
Albireo Pharma Inc
ALBO
+$10M
3
AZN icon
AstraZeneca
AZN
+$7.74M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$6.51M
5
KROS icon
Keros Therapeutics
KROS
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 59.53%
2 Technology 8.91%
3 Materials 1.8%
4 Consumer Discretionary 1.48%
5 Utilities 1.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$79.8B
$75.1M 12.55%
+420,900
New +$77.5M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$30.7M 5.13%
+75,000
New +$29.9M
SNY icon
3
Sanofi
SNY
$103B
$28.8M 4.82%
529,515
-30,000
-5% -$1.46M
NICE icon
4
Nice
NICE
$5.79B
$26.4M 4.42%
+115,482
New +$24.3M
AZN icon
5
AstraZeneca
AZN
$263B
$19.8M 3.31%
142,530
-57,500
-29% -$7.74M
JNJ icon
6
Johnson & Johnson
JNJ
$618B
$18.6M 3.1%
119,831
+10,000
+9% +$1.61M
TEVA icon
7
Teva Pharmaceuticals
TEVA
$40.8B
$18M 3.02%
+2,039,500
New +$20.2M
TEVA icon
8
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$18M 3.01%
2,037,000
-185,300
-8% -$1.83M
MSFT icon
9
Microsoft
MSFT
$3.45T
$15.7M 2.63%
+54,623
New +$13.9M
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.69B
$14.4M 2.41%
683,061
-27,500
-4% -$684K
MRK icon
11
Merck
MRK
$322B
$12.8M 2.14%
120,600
– –
NVO
12
Novo Nordisk
NVO
$208B
$11.4M 1.9%
143,080
– –
LLY icon
13
Eli Lilly
LLY
$1.02T
$10.9M 1.82%
31,690
+6,000
+23% +$2.02M
NTR icon
14
Nutrien
NTR
$33.2B
$10.7M 1.8%
+145,466
New +$11.2M
INZY
15
DELISTED
Inozyme Pharma
INZY
$10.2M 1.71%
1,781,858
+156,800
+10% +$414K
ABBV icon
16
AbbVie
ABBV
$443B
$10M 1.68%
63,000
+3,000
+5% +$459K
BIIB icon
17
Biogen
BIIB
$30B
$9.32M 1.56%
33,516
+26,000
+346% +$7.19M
BBIO icon
18
BridgeBio Pharma
BBIO
$15.7B
$9.32M 1.56%
+561,983
New +$6.55M
AMZN icon
19
Amazon
AMZN
$2.92T
$8.85M 1.48%
+85,680
New +$8.28M
QQQ icon
20
Invesco QQQ Trust
QQQ
$453B
$8.46M 1.41%
+26,353
New +$7.78M
SWTX
21
DELISTED
SpringWorks Therapeutics
SWTX
$8.18M 1.37%
317,625
+1,000
+0.3% +$29.2K
PTCT icon
22
PTC Therapeutics
PTCT
$5.68B
$7.71M 1.29%
+159,100
New +$7.27M
ENLT icon
23
Enlight Renewable Energy
ENLT
$11.8B
$7.63M 1.27%
+450,864
New +$7.61M
KURA icon
24
Kura Oncology
KURA
$800M
$7.38M 1.23%
603,287
+45,000
+8% +$562K
RARE icon
25
Ultragenyx Pharmaceutical
RARE
$2.45B
$7.37M 1.23%
183,696
– –
1
2 3 4

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2023 Portfolio in Review

As of Q1 2023, Sphera Funds Management held 102 positions worth $598M, up 28% from $466M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sphera Funds Management deployed $140M of net new capital in Q1 2023, opening 38 new positions and adding to 16 existing holdings. Its largest new stake was Nice: 115,482 shares worth $26.4M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 60% a quarter earlier, followed by Technology and Materials.

On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $10.9M trimmed.

  • Sphera Funds Management's largest Q1 2023 buy was Nice: 115,482 shares worth $26.4M.
  • Sphera Funds Management added most to Biogen in Q1 2023, an estimated $7.19M increase.
  • Sphera Funds Management's biggest Q1 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $10.9M.
  • Sphera Funds Management fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $10M.
  • Sphera Funds Management's ten largest holdings make up 44% of its $598M portfolio in Q1 2023.
  • Sphera Funds Management opened 38 new positions and closed 21 in Q1 2023.
  • Sphera Funds Management's portfolio value rose 28% quarter-over-quarter to $598M.

Based on Sphera Funds Management's 13F filing for Q1 2023, filed 15 May 2023.